Nathalie Guedj, Guillaume Cléry, Anaïs Chassac, Nathalie Colnot, Vinciane Rebours, Jérôme Cros, Louis de Mestier, Anne Couvelard, Matthieu Tihy
{"title":"Clinical application of digital pathology in small intestinal neuroendocrine tumours: proposal of a new G0 category.","authors":"Nathalie Guedj, Guillaume Cléry, Anaïs Chassac, Nathalie Colnot, Vinciane Rebours, Jérôme Cros, Louis de Mestier, Anne Couvelard, Matthieu Tihy","doi":"10.1530/EO-26-0061","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Small intestinal neuroendocrine tumours (siNETs) are usually indolent neoplasms, most of which are classified as grade 1 with very low proliferative activity. In practice, Ki-67 in G1 siNETs is often reported simply as '<3%', limiting prognostic discrimination. Digital pathology now enables reliable automated quantification of very low Ki-67 values. We investigated whether precise Ki-67 quantification could improve prognostic stratification in G1 siNETs.</p><p><strong>Methods: </strong>We retrospectively included 63 consecutive patients who underwent surgery for a G1 siNET at Beaujon Hospital between 2001 and 2017. Ki-67 was quantified on primary tumours (PTs) and, when available, lymph node and liver metastases, using QuPath automated image analysis. Ki-67 was assessed in the highest-proliferation hotspot (0.4 mm<sup>2</sup>; >2,000 tumour cells; Ki-67<sub>max</sub>) and as the mean of five hotspots (Ki-67<sub>mean</sub>). The primary endpoint was recurrence-free survival (RFS).</p><p><strong>Results: </strong>Among 63 patients, 33 underwent curative-intent surgery (median age: 56 years; 69% male). Median tumour size was 20 mm. At surgery, 87% were node-positive and 67% had synchronous metastases. Median Ki-67<sub>max</sub>/Ki-67<sub>mean</sub> in PTs was 0.99%/0.71%. In localised disease, Ki-67<sub>max</sub> predicted RFS (AUROC = 0.84). Median follow-up was 60.2 months. Median RFS was 112 months in patients with Ki-67<sub>max</sub> ≥1%, whereas no recurrences occurred in those with Ki-67<sub>max</sub> <1% (<i>P</i> = 0.04). Ki-67<sub>mean</sub> provided no additional prognostic value.</p><p><strong>Conclusion: </strong>Precise digital Ki-67 quantification refines prognostic stratification in G1 siNETs. Tumours with Ki-67 <1% may represent a biologically distinct 'G0' subgroup associated with extremely low recurrence risk after curative surgery.</p>","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"6 1","pages":"e260061"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615843/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine oncology (Bristol, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/EO-26-0061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Small intestinal neuroendocrine tumours (siNETs) are usually indolent neoplasms, most of which are classified as grade 1 with very low proliferative activity. In practice, Ki-67 in G1 siNETs is often reported simply as '<3%', limiting prognostic discrimination. Digital pathology now enables reliable automated quantification of very low Ki-67 values. We investigated whether precise Ki-67 quantification could improve prognostic stratification in G1 siNETs.
Methods: We retrospectively included 63 consecutive patients who underwent surgery for a G1 siNET at Beaujon Hospital between 2001 and 2017. Ki-67 was quantified on primary tumours (PTs) and, when available, lymph node and liver metastases, using QuPath automated image analysis. Ki-67 was assessed in the highest-proliferation hotspot (0.4 mm2; >2,000 tumour cells; Ki-67max) and as the mean of five hotspots (Ki-67mean). The primary endpoint was recurrence-free survival (RFS).
Results: Among 63 patients, 33 underwent curative-intent surgery (median age: 56 years; 69% male). Median tumour size was 20 mm. At surgery, 87% were node-positive and 67% had synchronous metastases. Median Ki-67max/Ki-67mean in PTs was 0.99%/0.71%. In localised disease, Ki-67max predicted RFS (AUROC = 0.84). Median follow-up was 60.2 months. Median RFS was 112 months in patients with Ki-67max ≥1%, whereas no recurrences occurred in those with Ki-67max <1% (P = 0.04). Ki-67mean provided no additional prognostic value.
Conclusion: Precise digital Ki-67 quantification refines prognostic stratification in G1 siNETs. Tumours with Ki-67 <1% may represent a biologically distinct 'G0' subgroup associated with extremely low recurrence risk after curative surgery.